Table SI. Clinicopathological characteristics of the 392 patients from the UMC Utrecht cohort.

Sex (Male/Female)	
Male	61.2%
Female	38.8%
Median age, years (Range)	62 (20-87)
KPS (<70/≥70)	27.8%/71.2% (missing: 1%, n=4)
Tumor volume, cc (Range)	37.16 (1-172)
Surgery	
Biopsy	17.3%
Debulking	82.7%
IDH1 (Wild type/ IDHR132 mutant)	81.6%/4.6% (missing: 13.8%, n=54)

Table SII. Multivariate Cox regression analysis for overall survival of 392 glioblastoma patients. The nuclear p-STAT5b immunohistochemical score is taken here as a continuous variable.

Variables in the Equation	P-value	HR	95% CI for HR	
			Lower	Upper
age at diagnosis	<0.001	1.037	1.024	1.049
KPS (<70 versus >70)	<0.001	2.283	1.731	3.01
Biopsy vs. debulking	0.17	1.367	0.875	2.137
IDH1 R132H gene (Wild Type versus Mutant)	0.061	2.202	0.964	5.029
Nuclear p-STAT5b IHC score (continuous)	<0.001	1.222	1.111	1.346

KPS, Karnofsky Performance Scale score; CI, confidence interval; HR, hazard ratio.

Table SIII. Densitometric analysis of the western blot gels.

Figure 2A	GAPDH	STAT5b	Staa5b/GAPDH	relative to control		
	10,048	133	0.013196656	1	si cont	U87
	11,321	0.326	2.8796E-05	0.002182071	si STAT5b	
	11,753	5	0.000386625	1	si cont	U87viii
	11,014	0.78	7.0819E-05	0.183172361	si STAT5b	
	8,898	30	0.003329962	1	si cont	LN18
	8,693	4	0.00046014	0.138181869	si STAT5b	
	9,199	27	0.002926296	1	si cont	GM3
	9,857	2	0.000190727	0.065177063	si STAT5b	
	9,987	18	0.001803645	1	si cont	GM2
	9,232	0.647	7.00823E-05	0.038855946	si STAT5b	
Figure 2D	p27	GAPDH	p27/GAPDH	relative to control		

	13894.095	16697.075	0.832127483	1	si cont	U87
	13858.045	20028.752	0.691907564	0.831492262	si STAT5b	
	26759.844	21149.924	1.265245398	1	si cont	U87viii
	26405.229	24952.631	1.058214222	0.836370734	si STAT5b	
	5690.518	19581.832	0.290601921	1	si cont	LN18
	4515.933	19179.66	0.235454278	0.810229599	si STAT5b	
	7655.882	18629.903	0.410945886	1	si cont	GM3
	7889.175	21930.581	0.359733971	0.875380393	si STAT5b	
	14208.53	19680.974	0.72194242	1	si cont	GM2
	7348.731	20983.338	0.350217444	0.485104399	si STAT5b	
Figure 2E	Cyclin D1	GAPDH	CyclinD1/GAPDH	relative to control		
	15824.853	15286.974	1.035185446	1	si cont	U87
	21958.631	15925.045	1.378874031	1.332006779	si STAT5b	
	3392.589	18420.066	0.184178982	1	si cont	U87viii
	5099.731	17890.409	0.285053908	1.547700531	si STAT5b	
	6244.589	11310.56	0.552102548	1	si cont	LN18
	11521.388	8849.368	1.301944726	2.35815743	si STAT5b	
	2441.619	10244.56	0.238333223	1	si cont	GM3
	4108.539	11260.974	0.36484757	1.530829676	si STAT5b	
	15966.359	8115.66	1.967351885	1	si cont	GM2
	23647.995	3757.246	6.293970371	3.199209261	si STAT5b	
Figure S4	Bcl-XL	GAPDH	Bcl-XL/GAPDH	relative to control		

	50166.785	17907.723	2.801405014	1	si cont	U87
	56620.664	20189.551	2.804453848	1.001088323	si STAT5b	
	39016.907	16677.723	2.339462467	1	si cont	U87viii
	40788.563	16985.501	2.401375326	1.026464566	si STAT5b	
	38824.25	9908.874	3.918129345	1	si cont	LN18
	39070.907	10278.924	3.801069742	0.970123599	si STAT5b	
	39018.492	10545.752	3.69992505	1	si cont	GM3
	36423.907	9934.459	3.666420788	0.990944611	si STAT5b	
	48942.392	13870.945	3.52841079	1	si cont	GM2
	48932.016	13290.409	3.681753963	1.043459558	si STAT5b	
Figure S5	GAPDH	PDL1	PDL1/GAPDH	relative to control		
	9,964	8,944	0.897631473	1	si cont	U87
	9,836	11,336	1.152501017	1.283935614	si STAT5b	
	13	0.647	0.050840798	1	si cont	U87viii
	13	0.655	0.04995805	0.982637018	si STAT5b	
	9,667	23,685	2.450087928	1	si cont	LN18
	9,484	24,825	2.617566428	1.068356118	si STAT5b	
	9,916	10,699	1.078963292	1	si cont	GM3
	9,730	11,040	1.134635149	1.051597545	si STAT5b	
	7,721	3,092	0.400466261	1	si cont	GM2
	7,844	5,078	0.647373789	1.616550137	si STAT5b	

5